透析患者的难治性高血压
本文为综述,聚焦接受肾脏替代治疗(含透析)患者的难治性高血压问题,涵盖高血压定义与治疗目标及其局限与偏倚、病理生理与血压评估、难治性高血压管理以及终末期肾病中表观治疗抵抗性高血压的患病率数据。作者结论认为,需在透析的终末期肾病人群中开展更大样本、更高质量的药物依从性研究,并需确定血压测量方式与时机、真正的目标血压值,重新审视该人群难治性高血压的定义及其与亚临床和临床终点的关系。
要点
- 现行难治性高血压定义基于一般人群,不能直接适用于终末期肾病透析人群。
- 真性难治性高血压的诊断需确认治疗依从性,并以动态或家庭血压测量确认血压未控制。
- 表观治疗抵抗性高血压指使用≥3类降压药血压仍未控制,或使用≥4类药物而不论血压水平。
核心结论
- 作者认为,应在接受透析的终末期肾病患者中开展更大样本、更高质量的药物依从性研究。
- 作者认为,应确定透析患者血压测量方式和时机,并明确该人群真正的目标血压值。
- 作者认为,应重新审视该人群难治性高血压的定义,并建立其与亚临床和临床终点的关系。
研究设计与样本
- 本文为综合性综述,聚焦接受肾脏替代治疗患者的难治性高血压。
- 综述内容涵盖高血压定义与治疗目标及其局限与偏倚、病理生理与血压评估、难治性高血压管理及终末期肾病中表观治疗抵抗性高血压的患病率数据。
主要发现
- 高血压是慢性肾脏病患者最常见的表现,患病率随疾病分期和病因不同为60%至90%。
- 高血压是心血管疾病、进展至终末期肾病和死亡的重要独立危险因素。
- 现行难治性高血压定义基于一般人群,不能直接适用于终末期肾病情况。
- 真性难治性高血压的诊断需确认治疗依从性,并以动态血压测量或家庭血压测量确认血压未控制。
- 表观治疗抵抗性高血压定义为使用三类或以上降压药血压仍未控制,或使用四类或以上药物而不论血压水平。
关键数值与推荐
- 一般人群难治性高血压定义:足量使用三种或以上降压药血压仍未控制,或使用四种或以上降压药类别而不论血压控制情况,前提是降压治疗包含利尿剂。
- 表观治疗抵抗性高血压定义:使用三类或以上降压药类别血压仍未控制,或使用四类或以上药物而不论血压水平。
- 真性难治性高血压诊断要求:确认治疗依从性,并以动态血压测量或家庭血压测量确认血压未控制。
局限性
- 原文指出目前确立的难治性高血压定义不能直接适用于终末期肾病情况。
- 原文指出综述涉及的定义与治疗目标存在局限与偏倚。
- 原文结论提出需开展更大样本、更高质量的药物依从性研究,并需确定血压测量方式与时机及真正的目标血压值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension is the most common finding in chronic kidney disease patients, with prevalence ranging from 60% to 90% depending on the stage and etiology of the disease. It is also a significant independent risk factor for cardiovascular disease, progression to end-stage kidney disease and mortality. According to the current guidelines, resistant hypertension is defined in the general population as uncontrolled blood pressure on three or more antihypertensive drugs in adequate doses or when patients are on four or more antihypertensive drug categories irrespective of the blood pressure control, providing that antihypertensive treatment included diuretics. The currently established definitions of resistant hypertension are not directly applicable to the end-stage kidney disease setting. The diagnosis of true resistant hypertension requires confirmation of adherence to therapy and confirmation of uncontrolled blood pressure values by ambulatory blood pressure measurement or home blood pressure measurement. In addition, the term "apparent treatment-resistant hypertension," defined as an uncontrolled blood pressure on three or more antihypertensive medication classes, or use of four or more medications regardless of blood pressure level was introduced. In this comprehensive review we focused on the definitions of hypertension, and therapeutic targets in patients on renal replacement therapy, including the limitations and biases. We discussed the issue of pathophysiology and assessment of blood pressure in the dialyzed population, management of resistant hypertension as well as available data on prevalence of apparent treatment-resistant hypertension in end-stage kidney disease. To conclude, larger sample-size and even higher quality studies about drug adherence should be conducted in the population of patients with the end-stage kidney disease who are on dialysis. It also should be determined how and when blood pressure should be measured in the group of dialysis patients. Additionally, it should be stated what the target blood pressure values in this group of patients really are. The definition of resistant hypertension in this group should be revisited, and its relationship to both subclinical and clinical endpoints should be established.
引用
- Symonides B, Lewandowski J, Małyszko J, et al. Resistant hypertension in dialysis. Nephrol Dial Transplant. 2023. PMID: 36898677. doi:10.1093/ndt/gfad047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。